Gout

Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology.

WASHINGTON — SGLT2 inhibitors can reduce the need for urate-lowering and flare therapies, and lower the odds of gout-centric medical visits, in patients with gout alongside type 2 diabetes, according to a speaker at ACR Convergence 2024.

WASHINGTON — The use of colchicine for gout flare prevention imparts a “modest” decrease in the risk for knee or hip replacement over several years, according to a study presented at ACR Convergence 2024.

WASHINGTON — Different stages of gout treatment may call for different serum urate targets, with certain levels being better for dissolving or preventing monosodium urate crystals, according to data presented at ACR Convergence 2024.

A genetic predisposition for gout predicts an increased risk for cardiovascular disease, but a healthy lifestyle can curb that risk, according to data published in RMD Open.

Machine learning can be combined with Raman spectroscopy to objectively identify gout-causing crystals in synovial fluid and diagnose the condition with high certainty, according to data published in Rheumatology.

Beer and ciders outranked spirits, red wine and other types of alcohol in elevating the risk for gout among men and women, according to a study published in JAMA Network Open.

U.S. adults with higher triglyceride glycemic index scores demonstrate a greater likelihood of developing gout, according to data published in the Journal of Health, Population and Nutrition.

Allopurinol and febuxostat were both associated with lower all-cause mortality when used by adults undergoing hemodialysis in Japan; allopurinol also lowered risk of death from CVD events, according to study data.

The FDA has approved an updated label for Gloperba, an oral liquid colchicine formulation, allowing for precision dosing, according to a press release from Scilex Holding Company.